

# Sergey N Mosolov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5147823/publications.pdf>

Version: 2024-02-01

59  
papers

4,104  
citations

257450

24  
h-index

155660

55  
g-index

63  
all docs

63  
docs citations

63  
times ranked

4077  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. <i>Nature Medicine</i> , 2007, 13, 1102-1107.	30.7	1,003
2	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 318-378.	2.6	498
3	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 154-219.	2.6	344
4	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 2-44.	2.6	343
5	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 81-109.	2.6	322
6	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 85-116.	2.6	302
7	Mixed Features in Patients With a Major Depressive Episode. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e351-e358.	2.2	136
8	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 2-58.	2.6	128
9	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 142-170.	2.6	106
10	Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. <i>Bipolar Disorders</i> , 2015, 17, 795-803.	1.9	91
11	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 82-90.	2.4	61
12	Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. <i>International Clinical Psychopharmacology</i> , 2010, 25, 60-67.	1.7	59
13	Antidepressant-induced hypomania/mania in patients with major depression: Evidence from the BRIDGE-II-MIX study. <i>Journal of Affective Disorders</i> , 2017, 219, 187-192.	4.1	47
14	Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis. <i>European Neuropsychopharmacology</i> , 2019, 29, 825-834.	0.7	41
15	Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-Mix study. <i>Bipolar Disorders</i> , 2017, 19, 458-464.	1.9	34
16	Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. <i>Annals of General Psychiatry</i> , 2012, 11, 1.	2.7	31
17	Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 362-372.	4.5	31
18	Primary and Secondary Negative Symptoms in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 766692.	2.6	31

#	ARTICLE	IF	CITATIONS
19	Validation of the Russian version of the Hypomania Checklist (HCL-32) for the detection of Bipolar II disorder in patients with a current diagnosis of recurrent depression. <i>Journal of Affective Disorders</i> , 2014, 155, 90-95.	4.1	30
20	Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study. <i>Journal of Affective Disorders</i> , 2018, 229, 164-170.	4.1	28
21	Relationships between mixed features and borderline personality disorder in 2811 patients with major depressive episode. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 133-143.	4.5	27
22	The role of overlapping excitatory symptoms in major depression: are they relevant for the diagnosis of mixed state?. <i>Journal of Psychiatric Research</i> , 2019, 115, 151-157.	3.1	27
23	Stress, anxiety, depression and burnout in frontline healthcare workers during two peaks of COVID-19 pandemic in Russia. <i>Psychiatry Research</i> , 2021, 306, 114226.	3.3	27
24	STRESS AND ANXIETY AMONG HEALTHCARE WORKERS ASSOCIATED WITH COVID-19 PANDEMIC IN RUSSIA. <i>Psychiatria Danubina</i> , 2020, 32, 549-556.	0.4	27
25	Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation. <i>Acta Psychiatrica Scandinavica</i> , 2006, 114, 223-231.	4.5	26
26	Bipolar <scp>II</scp> disorder in patients with a current diagnosis of recurrent depression. <i>Bipolar Disorders</i> , 2014, 16, 389-399.	1.9	26
27	A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25â€“50mg) in patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2014, 24, 553-563.	0.7	26
28	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25â€“50â€“mg/day) versus escitalopram (10â€“20â€“mg/day) in out-patients with severe generalized anxiety disorder. <i>European Neuropsychopharmacology</i> , 2018, 28, 970-979.	0.7	25
29	The implications of hypersomnia in the context of major depression: Results from a large, international, observational study. <i>European Neuropsychopharmacology</i> , 2019, 29, 471-481.	0.7	24
30	Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. <i>International Journal of Clinical Practice</i> , 2009, 63, 1249-1258.	1.7	20
31	Design and validation of standardized clinical and functional remission criteria in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 167.	2.2	19
32	Towards a framework for treatment effectiveness in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1867.	2.2	18
33	Symptom networks in acute depression across bipolar and major depressive disorders: A network analysis on a large, international, observational study. <i>European Neuropsychopharmacology</i> , 2020, 35, 49-60.	0.7	18
34	The relationship between attention deficit hyperactivity disorder, bipolarity and mixed features in major depressive patients: Evidence from the BRIDGE-II-Mix Study. <i>Journal of Affective Disorders</i> , 2019, 246, 346-354.	4.1	14
35	Factors associated with single versus multiple suicide attempts in depressive disorders. <i>Journal of Affective Disorders</i> , 2020, 277, 306-312.	4.1	13
36	Sultans of Swing. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	12

#	ARTICLE	IF	CITATIONS
37	Relationships between recurrence and polarity in major depressive disorders: Pooled analysis of the BRIDGE and BRIDGE-II-MIX cohorts. <i>Journal of Affective Disorders</i> , 2019, 256, 250-258.	4.1	11
38	Do depressive and manic symptoms differentially impact on functioning in acute depression? Results from a large, cross-sectional study. <i>Journal of Affective Disorders</i> , 2020, 261, 30-39.	4.1	11
39	Management of schizophrenia: clinical experience with asenapine. <i>Journal of Psychopharmacology</i> , 2013, 27, 14-22.	4.0	10
40	Deconstructing major depressive episodes across unipolar and bipolar depression by severity and duration: a cross-diagnostic cluster analysis on a large, international, observational study. <i>Translational Psychiatry</i> , 2020, 10, 241.	4.8	9
41	The role of different patterns of psychomotor symptoms in major depressive episode: Pooled analysis of the BRIDGE and BRIDGE-II-MIX cohorts. <i>Bipolar Disorders</i> , 2019, 21, 785-793.	1.9	7
42	Characterization of rapid cycling bipolar patients presenting with major depressive episode within the BRIDGE-II-MIX study. <i>Bipolar Disorders</i> , 2021, 23, 391-399.	1.9	7
43	Quetiapine in the treatment of patients with resistant auditory hallucinations: two case reports with long-term cognitive assessment. <i>European Psychiatry</i> , 2005, 20, 430-430.	0.2	4
44	Electroconvulsive Therapy (ECT) in Bipolar Disorder Patients with Ultra-Rapid Cycling and Unstable Mixed States. <i>Medicina (Lithuania)</i> , 2021, 57, 624.	2.0	4
45	The risk of developing cardiovascular disease in bipolar disorder. Clinical and social factors. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1556-1561.	0.8	4
46	THE COMBINED EFFECT OF CYP2D6 AND DRD2 Taq1A POLYMORPHISMS ON THE ANTIPSYCHOTICS DAILY DOSES AND HOSPITAL STAY DURATION IN SCHIZOPHRENIA INPATIENTS (OBSERVATIONAL NATURALISTIC) <i>Tj ETQq</i> 0.0 rgB5/Overlock	0.4	0
47	Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression in schizophrenia patients. <i>Annals of General Psychiatry</i> , 2008, 7, .	2.7	2
48	REMISSION IN SCHIZOPHRENIA: RESULTS OF POPULATION AND PHARMACOTHERAPEUTIC STUDIES OF SCHIZOPHRENIC OUTPATIENTS. <i>Schizophrenia Research</i> , 2010, 117, 495-496.	2.0	2
49	mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial. <i>Neuroscience and Behavioral Physiology</i> , 2011, 41, 559-566.	0.4	1
50	Incidence of the Diagnosis of Anxiety Disorders in the Russian Federation: Results of a Web-Based Survey of Psychiatrists. <i>Neurology and Therapy</i> , 2021, 10, 971-984.	3.2	1
51	G.Ya. Avrutsky – a founder of Russian clinical psychopharmacology (to 90th anniversary of birth). <i>Zhurnal Nevrologii i Psikiatrii Imeni S S Korsakova</i> , 2015, 115, 60.	0.7	1
52	The risk of developing cardiovascular disease in bipolar disorder. Biological factors and therapy. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 579-583.	0.8	1
53	Dynamics of Electroencephalogram Spectral Characteristics during Use of Transcranial Magnetic Stimulation in Patients with Refractory Depression. <i>Neuroscience and Behavioral Physiology</i> , 2017, 47, 281-287.	0.4	0
54	Functioning Problems in Persons with Schizophrenia in the Russian Context. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10276.	2.6	0

#	ARTICLE	IF	CITATIONS
55	Questionnaire for initial self-assessment in post-COVID period: Recommendations of Multidisciplinary expert board on screening of post-COVID syndrome during an expanded medical check-up. Pulmonologiya, 2021, 31, 599-612.	0.8	0
56	The electroencephalographic profile of depressions with atypical features in recurrent depressive and bipolar affective type II disorders. Russian Psychiatric Journal, 2021, , 59-72.	0.2	0
57	Screening for hypomania among patients with recurrent depression using the new HCL-33 questionnaire. Russian Psychiatric Journal, 2021, , 59-69.	0.2	0
58	Validation of the Russian version of Stress and Anxiety to Viral Epidemics â€“ 9 items (SAVE-9) among healthcare workers during COVID-19 pandemic. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 45-51.	1.2	0
59	Depression with Mixed Features (for DSM-5): Distinguishing Indicators Imaginary Coherence EEG Rest. Psychiatry, 2021, 19, 61-75.	0.7	0